Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years at time of signing informed consent form * Signed informed consent form * Histological confirmation of RCC with a Clear-cell component, including subject who also have a sarcomatoïd feature * Advanced (not amenable to curative surgery or radiation therapy) or Metastatic RCC (American Joint Committee on Cancer \[AJCC\] Stage IV) * Participants with good or intermediate risk with only one adverse prognostic factor will be eligible as per International Metastatic RCC Database Consortium (IMDC) criteria * Prior first line therapy for mRCC with the combination of PD-1/ PD-L1 ICI plus VEGFR-TKI * First line treatment with the combination of PD-1/PD-L1 ICI and VEGFR-TKI must be ongoing whatever the dose with no period of discontinuation \> 6 consecutive weeks during treatment of the PD-1/PD-L1 ICI, and 2 consecutive weeks in the last 3 months before randomisation for the VEGFR-TKI * Patients with an objective response (complete response or partial response) between the end of 11th month and the end of the 13th month of the combination treatment with PD-1/PD-L1 ICI and VEGFR-TKI. CT scan at the initiation of this treatment must be available. * Karnofsky Performance Status (KPS) grade ≥ 70% * Measurable disease as per RECIST v1.1 per investigator on CT scan at the initiation of first line treatment with combination treatment with PD-1/PD-L1 ICI and VEGFR-TKI * Adequate organ function * Females of childbearing potential must use a highly effective contraception (combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral ; intravaginal ;transdermal) ; progestogen-only hormonal contraception associated with inhibition of ovulation (oral ; injectable ; implantable ; intrauterine device (IUD) ; intrauterine hormone-releasing system ( IUS)) ; bilateral tubal occlusion ; vasectomised partner ; sexual abstinence) and continue its use for 5 months after the last PD1/PD L1 ICI administration. * Sexually active male patients must agree to use condoms and continue its use for 5 months after the last PD1/PD L1 ICI administration. * Willingness and ability to comply with study procedures. * Patient affiliated to a social security system or benefit from the same system Exclusion Criteria: * Prior therapy with PD-1/PD-L1 ICI or VEGFR-TKI monotherapy. * Poorly controlled hypertension despite antihypertensive therapy * More than one adverse prognostic factor (IMDC criteria) * Women who are pregnant or lactating; * Current participation in an investigational program * Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study * Adults who are the subject of legal protection measures * Persons deprived of their liberty by a judicial or administrative decision